Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation

被引:5
|
作者
Samaras, Athanasios [1 ]
Vrana, Eleni [1 ]
Kartas, Anastasios [1 ]
Moysidis, Dimitrios, V [1 ]
Papazoglou, Andreas S. [1 ]
Doundoulakis, Ioannis [1 ]
Fotos, George [1 ]
Rampidis, Georgios [1 ]
Tsalikakis, Dimitrios G. [2 ]
Efthimiadis, Georgios [1 ]
Karvounis, Haralambos [1 ]
Tzikas, Apostolos [1 ,3 ]
Giannakoulas, George [1 ]
机构
[1] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Cardiol 1, St Kiriakidi 1, Thessaloniki 54636, Greece
[2] Univ Western Macedonia, Dept Informat & Telecommun Engn, Kozani, Greece
[3] Interbalkan European Med Ctr, Thessaloniki, Greece
关键词
Valvular heart disease; Stenosis; Regurgitation; Atrial fibrillation; Prognosis; Outcomes; THROMBOEMBOLIC EVENTS; ANTICOAGULATED PATIENTS; MITRAL REGURGITATION; EUROPEAN ASSOCIATION; ORAL ANTICOAGULANTS; VALVE DISEASE; WARFARIN; AF; EPIDEMIOLOGY; OUTCOMES;
D O I
10.1186/s12872-021-02264-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Valvular heart disease (VHD) in non-valvular atrial fibrillation (AF) is a puzzling clinical entity. The aim of this study was to evaluate the prognostic effect of significant VHD (sVHD) among patients with non-valvular AF. Methods This is a post-hoc analysis of the MISOAC-AF trial (NCT02941978). Consecutive inpatients with non-valvular AF who underwent echocardiography were included. sVHD was defined as the presence of at least moderate aortic stenosis (AS) or aortic/mitral/tricuspid regurgitation (AR/MR/TR). Cox regression analyses with covariate adjustments were used for outcome prediction. Results In total, 983 patients with non-valvular AF (median age 76 [14] years) were analyzed over a median follow-up period of 32 [20] months. sVHD was diagnosed in 575 (58.5%) AF patients. sVHD was associated with all-cause mortality (21.6%/yr vs. 6.5%/yr; adjusted HR [aHR] 1.55, 95% confidence interval [CI] 1.17-2.06; p = 0.02), cardiovascular mortality (16%/yr vs. 4%/yr; aHR 1.70, 95% CI 1.09-2.66; p = 0.02) and heart failure-hospitalization (5.8%/yr vs. 1.8%/yr; aHR 2.53, 95% CI 1.35-4.63; p = 0.02). The prognostic effect of sVHD was particularly evident in patients aged < 80 years and in those without history of heart failure (p for interaction < 0.05, in both subgroups). After multivariable adjustment, moderate/severe AS and TR were associated with mortality, while AS and MR with heart failure-hospitalization. Conclusion Among patients with non-valvular AF, sVHD was highly prevalent and beared high prognostic value across a wide spectrum of clinical outcomes, especially in patients aged < 80 years or in the absence of heart failure. Predominantly AS, as well as MR and TR, were associated with worse prognosis.
引用
下载
收藏
页数:12
相关论文
共 50 条
  • [21] RISK OF RECURRENT STROKE IN PATIENTS WITH ATRIAL-FIBRILLATION AND NON-VALVULAR HEART-DISEASE
    SAGE, JI
    VANUITERT, RL
    STROKE, 1983, 14 (04) : 537 - 540
  • [22] PROGNOSTIC PERFORMANCE OF MECKI SCORE IN HEART FAILURE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION TREATED WITH EDOXABAN
    Mapelli, M.
    Mattavelli, I
    Salvioni, E.
    Bonomi, A.
    Capra, N.
    Vignati, C.
    Cattadori, G.
    Agostoni, P.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2024, 26 : ii92 - ii92
  • [23] The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey
    Molteni, Mauro
    Friz, Hernan Polo
    Primitz, Laura
    Marano, Giuseppe
    Boracchi, Patrizia
    Cimminiello, Claudio
    EUROPACE, 2014, 16 (12): : 1720 - 1725
  • [24] PROGNOSTIC VALUE OF HEART FAILURE FOR THE PREDICTION OF LEFT ATRIAL THROMBUS PERSISTENCE IN NON-VALVULAR ATRIAL FIBRILLATION
    Kowalczyk, Ewelina
    Kasprzak, Jaroslaw
    Lipiec, Piotr
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A820 - A820
  • [25] Novel Anticoagulants for Non-valvular Atrial Fibrillation
    Xu, Bo
    Whitbourn, Robert
    HEART LUNG AND CIRCULATION, 2012, 21 (08): : 463 - 467
  • [26] Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
    Breithardt, Guenter
    Baumgartner, Helmut
    Berkowitz, Scott D.
    Hellkamp, Anne S.
    Piccini, Jonathan P.
    Lokhnygina, Yuliya
    Halperin, Jonathan L.
    Singer, Daniel E.
    Hankey, Graeme J.
    Hacke, Werner
    Becker, Richard C.
    Nessel, Christopher C.
    Mahaffey, Kenneth W.
    Califf, Robert M.
    Fox, Keith A. A.
    Patel, Manesh R.
    HEART, 2016, 102 (13) : 1036 - 1043
  • [27] Non-valvular atrial fibrillation and stroke prevention
    Hankey, GJ
    MEDICAL JOURNAL OF AUSTRALIA, 2001, 174 (05) : 234 - 239
  • [28] Echocardiographic predictors of non-valvular atrial fibrillation
    David, C
    Almeida, A
    Marques, P
    Oliveira, EI
    Rodrigues, S
    Vagueiro, MC
    EUROPEAN HEART JOURNAL, 2003, 24 : 388 - 388
  • [29] Newer Anticoagulants for Non-Valvular Atrial Fibrillation
    Harburger, Joseph M.
    Aronow, Wilbert S.
    PHARMACEUTICALS, 2012, 5 (05) : 469 - 480
  • [30] Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
    Manar Yossef
    Reham Amer
    Hatem Elsokkary
    Gamal Shama
    Middle East Current Psychiatry, 30